Physician profile
Amy E Smith
NPI 1265530471
$7,057.78
in general payments reported to CMS, 2019-2025
31 companies · $14.33 in 2025
The $14.33 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,092 · 2022: $3,830 · 2023: $1,748 · 2024: $375 · 2025: $14.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,030.34 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Novo Nordisk INC | $1,316.77 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $567.62 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $470.69 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.88 | 2021-2024 | |
| Dexcom, INC. | $274.15 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $267.52 | 2021-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $259.68 | 2021-2022 | |
| Horizon Therapeutics Plc | $201.82 | 2021-2022 | |
| Corcept Therapeutics | $198.41 | 2021-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.43 | 2022-2023 | Jardiance |
| Amgen INC. | $137.13 | 2021-2025 | Prolia, Evenity, Tepezza |
| Abbvie INC. | $133.38 | 2021-2024 | |
| Nevro Corp. | $96.73 | 2021 | |
| Xeris Pharmaceuticals, INC. | $89.55 | 2022-2024 | Recorlev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $85.21 | 2022-2023 | Omnipod |
| Recordati_rare_diseases_inc. | $60.31 | 2022-2024 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $56.64 | 2022-2024 | Unithroid |
| Tandem Diabetes Care, INC. | $43.72 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Grt US Holding, INC. | $41.06 | 2022 | |
| Opko Pharmaceuticals, LLC | $33.86 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.71 | 2022 | |
| Eisai INC. | $24.18 | 2023 | |
| Blueprint Medicines Corporation | $21.78 | 2021 | |
| Averitas Pharma INC. | $20.90 | 2023 | Qutenza |
| Amryt Pharma Holdings Ltd | $20.77 | 2023 | Mycapssa |
| Astellas Pharma US INC | $18.28 | 2023 | Veozah |
| Chiesi USA, INC. | $17.93 | 2024 | Mycapssa |
| Ibsa Pharma INC. | $17.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.